Pharmacologic modulation of ACE2 expression

Current Hypertension Reports

Volumn 10, Issue 5, 2008, Pages 410-414

  Soler, María José ^b   Barrios, Clara ^b   Oliva, Raymond ^b   Batlle, Daniel ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

ACE2 Activity; ACE2 Protein; Eplerenone; Olmesartan; Telmisartan

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ENALAPRIL; EPLERENONE; LISINOPRIL; LOSARTAN; OLMESARTAN; SPIRONOLACTONE; TELMISARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; GENE AMPLIFICATION; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; PROTEIN EXPRESSION; BIOSYNTHESIS; DISEASE COURSE; DRUG EFFECT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; HUMANS; HYPERTENSION; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 58149402305     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-008-0076-0     Document Type: Article

References (45)

1. Danilczyk U, Penninger JM: Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 2006, 98:463–471.
2. Tipnis SR, Hooper NM, Hyde R, et al.: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000, 275:332 38–332 43.
3. Donoghue M, Hsieh F, Baronas E, et al.: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 2000, 87:E1–E9.
4. Crackower MA, Sarao R, Oudit GY, et al.: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822–828.
5. Xie X, Chen J, Wang X, et al.: Age-and gender-related difference of ACE2 expression in rat lung. Life Sci 2006, 78:2166–2171.
6. Valdes G, Neves LA, Anton L, et al.: Distribution of angiotensin-(1–7) and ACE2 in human placentas of normal and pathological pregnancies. Placenta 2006, 27:200–207.
7. Paizis G, Tikellis C, Cooper ME, et al.: Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 2005, 54:1790–1796.
8. Imai Y, Kuba K, Rao S, et al.: Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005, 436:112–116.
9. Hamming I, Timens W, Bulthuis ML, et al.: Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004, 203:631–637.
10. Doobay MF, Talman LS, Obr TD, et al.: Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007, 292:R373–R381.
11. Batlle D, Soler MJ, Wysocki J: New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2—a potential target for treatment of hypertension and diabetic nephropathy. Curr Opin Nephrol Hypertens 2008, 17:250–257.
12. Soler MJ, Wysocki J, Batlle D: ACE2 and the kidney. Exp Physiol 2008, 93:549–553.
13. Soler MJ, Wysocki J, Ye M, et al.: ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 2007, 72:614–623.
14. Tikellis C, Cooper ME, Bialkowski K, et al.: Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int 2006, 70:34–41.
15. Wysocki J, Ye M, Soler MJ, et al.: ACE and ACE2 activity in diabetic mice. Diabetes 2006, 55:2132–2139.
16. Ye M, Wysocki J, William J, et al.: Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006, 17:3067–3075.
17. Zhong JC, Huang DY, Yang YM, et al.: Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension 2004, 44:907–912.
18. Leehey DJ, Singh AK, Bast JP, et al.: Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. Transl Res 2008, 151:208–216.
19. Ye M, Wysocki J, Naaz P, et al.: Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004, 43:1120–1125.
20. Wysocki J, Gonzalez-Pacheco FR, Batlle D: Angiotensin-converting enzyme 2: possible role in hypertension and kidney disease. Curr Hypertens Rep 2008, 10:70–77.
21. Wong DW, Oudit GY, Reich H, et al.: Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 2007, 171:438–451.
22. Brosnihan KB, Neves LA, Joyner J, et al.: Enhanced renal immunocytochemical expression of ANG-(1–7) and ACE2 during pregnancy. Hypertension 2003, 42:749–753.
23. de Lang A, Osterhaus AD, Haagmans BL: Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology 2006, 353:474–481.
24. Keidar S, Gamliel-Lazarovich A, Kaplan M, et al.: Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 2005, 97:946–953.
25. Gallagher PE, Chappell MC, Ferrario CM, Tallant EA: Distinct roles for ANG II and ANG-(1–7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 2006, 290:C420–C426.
26. Koka V, Huang XR, Chung AC, et al.: Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 2008, 172:1174–1183.
27. Zulli A, Rai S, Buxton BF, et al.: Co-localization of angiotensin-converting enzyme 2-, octomer-4-and CD34-positive cells in rabbit atherosclerotic plaques. Exp Physiol 2008, 93:564–569.
28. Ji H, Menini S, Zheng W, et al.: Role of angiotensin-converting enzyme 2 and angiotensin(1–7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension. Exp Physiol 2008, 93:648–657.
29. Gupta A, Rhodes GJ, Berg DT, et al.: Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. Am J Physiol Renal Physiol 2007, 293:F245–F254.
30. Soler MJ, Wysocki J, William J, et al.: ACE2 is preferentially localized in the tunica media layer in renal vasculature and its expression increases after administration of a type 1 receptor antagonist [abstract]. Hypertension 2006, 48:E25–E103 LB 12.
31. Ocaranza MP, Godoy I, Jalil JE, et al.: Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 2006, 48:572–578.
32. Igase M, Strawn WB, Gallagher PE, et al.: Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1–7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005, 289:H1013–H1019.
33. Ferrario CM, Jessup J, Gallagher PE, et al.: Effects of renin-angiotensin system blockade on renal angiotensin-(1–7) forming enzymes and receptors. Kidney Int 2005, 68:2189–2196.
34. Takeda Y, Zhu A, Yoneda T, et al.: Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2007, 20:1119–1124.
35. Jessup JA, Gallagher PE, Averill DB, et al.: Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 2006, 291:H2166–H2172.
36. Agata J, Ura N, Yoshida H, et al.: Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006, 29:865–874.
37. Whaley-Connell AT, Chowdhury NA, Hayden MR, et al.: Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006, 291:F1308–F1314.
38. Yamamoto K, Ohishi M, Katsuya T, et al.: Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006, 47:718–726.
39. Oudit GY, Kassiri Z, Patel MP, et al.: Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 2007, 75:29–39.
40. Benson SC, Pershadsingh HA, Ho CI, et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993–1002.
41. Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 2005, 64:476–478.
42. Kobayashi N, Ohno T, Yoshida K, et al.: Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 2008, 21:576–581.
43. Tikellis C, Bialkowski K, Pete J, et al.: ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 2008, 57:1018–1025.
44. Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al.: Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008, 51:1312–1317.
45. Ye M, Wysocki J, Rodriguez E, et al.: Recombinant ACE2 attenuates angiotensin II induced hypertension [abstract]. Hypertension 2007, 50:e75–e155.